Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine
Authors:
- 16 September 2019
- journal article
- research article
- Published by Taylor & Francis in Current Eye Research
- Vol. 45 (3) , 327-338
Abstract
Vision researchers have been at the forefront of translational medicine and therapeutics at least in part due to the accessibility of ocular structures, the relative immune privilege of the ocular environment, well defined objective and subjective endpoints and sophisticated imaging modalities that harness the optical clarity of ocular media, permitting real-time submicron resolution of ocular structures and direct visualisation of the central nervous system. Despite these significant advances, primary open angle glaucoma remains the leading cause of irreversible blindness worldwide, where traditional IOP-lowering therapies are often not sufficient to prevent progression to blindness even for patients with access to high quality healthcare. Neuroprotection strategies, which aim to boost the ability of target cells to withstand a pathological insult, have shown significant promise in animal models but none have shown clinically relevant efficacy in human clinical trials to date. Here we outline the current status of neuroprotection clinical trials for glaucoma, including how refinements in clinical trial design may improve the prospects for ongoing and future glaucoma neuroprotection trials. We also consider how lessons learned from trials for other diseases may be used to guide the development of future glaucoma therapies. Finally, we discuss how advances in our understanding of the glaucomatous degenerative process may aid future neuroprotective strategies and tailoring of treatment according to an individual’s risk, thereby improving outcomes for our patients.Keywords
Funding Information
- Fight for Sight UK (1805)
- Wellcome Trust (104001/Z/14/Z)
This publication has 100 references indexed in Scilit:
- Retinal Ganglion Cell Dendritic Atrophy in DBA/2J GlaucomaPLOS ONE, 2013
- The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9–dependent innate immune responses in the liverBlood, 2011
- Method for comparing visual field defects to local RNFL and RGC damage seen on frequency domain OCT in patients with glaucomaBiomedical Optics Express, 2011
- Endothelin antagonism as an active principle for glaucoma therapyBritish Journal of Pharmacology, 2011
- Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunityFrontiers in Microbiology, 2011
- Neuroprotective Effects of Intravitreal Mesenchymal Stem Cell Transplantation in Experimental GlaucomaInvestigative Ophthalmology & Visual Science, 2010
- The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in miceJournal of Clinical Investigation, 2009
- Effect of CNTF on Retinal Ganglion Cell Survival in Experimental GlaucomaInvestigative Ophthalmology & Visual Science, 2009
- Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucomaJournal of Cell Biology, 2007
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006